{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novolog%C2%AE",
    "query": {
      "intervention": "Novolog®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 47,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novolog%C2%AE&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T01:16:12.186Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03211858",
      "title": "Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "NovoLog/NovoRapid",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (HOE901)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 597,
      "start_date": "2017-08-02",
      "completion_date": "2019-01-12",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 42,
      "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 35 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03211858"
    },
    {
      "nct_id": "NCT00127296",
      "title": "Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2",
        "Delivery Systems"
      ],
      "interventions": [
        {
          "name": "FlexPen®",
          "type": "DEVICE"
        },
        {
          "name": "vial and syringe",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "40 Years to 99 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-07",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-06",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127296"
    },
    {
      "nct_id": "NCT00773279",
      "title": "Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2",
        "Delivery Systems"
      ],
      "interventions": [
        {
          "name": "FlexTouch®",
          "type": "DEVICE"
        },
        {
          "name": "FlexPen®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2008-09",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 65,
      "location_summary": "Burlingame, California • Concord, California • Encino, California + 59 more",
      "locations": [
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773279"
    },
    {
      "nct_id": "NCT00467649",
      "title": "A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate (Symlin)",
          "type": "DRUG"
        },
        {
          "name": "rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])",
          "type": "DRUG"
        },
        {
          "name": "basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 112,
      "start_date": "2007-05",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2015-04-14",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 37,
      "location_summary": "Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467649"
    },
    {
      "nct_id": "NCT00913497",
      "title": "The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health West",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 16,
      "start_date": "2009-06",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00913497"
    },
    {
      "nct_id": "NCT05184868",
      "title": "AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "AT247",
          "type": "DRUG"
        },
        {
          "name": "NovoLog",
          "type": "DRUG"
        },
        {
          "name": "Fiasp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arecor Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-03",
      "completion_date": "2022-09-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184868"
    },
    {
      "nct_id": "NCT02670915",
      "title": "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Faster-acting insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin degludec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 834,
      "start_date": "2016-05-04",
      "completion_date": "2018-03-03",
      "has_results": true,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670915"
    },
    {
      "nct_id": "NCT01445951",
      "title": "Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin with MedTone C Inhaler",
          "type": "DRUG"
        },
        {
          "name": "Technosphere ®Insulin with Gen2 Inhaler",
          "type": "DRUG"
        },
        {
          "name": "Insulin Aspart in combination with a basal insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2011-09",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-10-22",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 58,
      "location_summary": "Burlingame, California • Escondido, California • Huntington Beach, California + 50 more",
      "locations": [
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445951"
    },
    {
      "nct_id": "NCT01680341",
      "title": "Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec/insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2012-08-31",
      "completion_date": "2013-08-22",
      "has_results": true,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 28,
      "location_summary": "Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01680341"
    },
    {
      "nct_id": "NCT03977727",
      "title": "FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Fiasp®",
          "type": "DRUG"
        },
        {
          "name": "Novolog®",
          "type": "DRUG"
        },
        {
          "name": "670G hybrid closed loop continuous subcutaneous insulin infusion system",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Texas Diabetes & Endocrinology, P.A.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-06-11",
      "completion_date": "2020-04-20",
      "has_results": true,
      "last_update_posted_date": "2020-09-29",
      "last_synced_at": "2026-09-08T01:16:12.186Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03977727"
    }
  ]
}